A Phase 3 interventional study of Aflibercept (EYLEA, BAY86-5321) and Topical IOP-lowering drugs in Glaucoma, Neovascular, sponsored by Bayer. Completed at 7 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-03-03.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The researchers in this trial want to learn how the drug aflibercept works in in Japanese patients with increased eye pressure that is caused by new blood vessels growing in the eye (neovascular glaucoma or NVG). They also want to find out how patient tolerate the application of the drug that is injected in the vitreous humor of the eye and if this will cause any medical problems during the trial (vitreous humor, also called vitreous body is the clear gel that fills the space between the lens and the retina of the eyeball).
39 studies on the registry are indexed under Glaucoma, Neovascular; 5 are open to participants now.
This study's enrollment of 16 is below the median of 40 across 32 interventional studies indexed under Glaucoma, Neovascular.
Browse Glaucoma, Neovascular studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Japanese patients with neovascular glaucoma
Drug: Aflibercept (EYLEA, BAY86-5321) · Drug: Topical IOP-lowering drugs
2 mg (0.05 mL), Intravitreal injection (IVT), single dose.
A combination of at least 3 topical IOP-lowering drugs will be administered during a run-in phase before treatment and should be kept unchanged until IOP evaluation at Week 1, after which they may be reduced according to the investigator's opinion
Change in Intraocular Pressure (IOP) From Baseline to Week 1
The primary efficacy analysis was on the changes in IOP from baseline to Week 1 (LOCF).
Time frame: Baseline and week 1
Percentage of Participants Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Week 1
NVI Grade: 0=No iris neovascularization; 1=Fine surface neovascularization of the pupillary zone of the iris involving less than two quadrants; 2=Surface neovascularization of the pupillary zone of the iris involving more than two quadrants; 3=In addition to neovascularization of the pupillary zone, neovascularization of the ciliary zone of the iris and/or ectropion uveae involving one to three quadrants; 4=In addition to neovascularization of the pupillary zone, neovascularization of the ciliary zone of the iris and/or ectropion uveae involving more than three quadrants. The change in NVI grades categorized to "Improved" means improvement by at least one grade from baseline.
Time frame: Baseline and week 1
Study was conducted at 7 study sites in Japan from 3-Oct-2018 (first subject's first visit) to 14-Mar-2019 (last subject's last visit).
| Milestone | Aflibercept 2 mg Intravitreal (IVT) Injection Group |
|---|---|
| Started | 16 |
| Received treatment | 16 |
| Completed | 15 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
The primary efficacy analysis was on the changes in IOP from baseline to Week 1 (LOCF).
| mmHg | Aflibercept 2 mg Intravitreal (IVT) Injection Group |
|---|---|
| Change in Intraocular Pressure (IOP) From Baseline to Week 1 | -8.3 ± 7.3 |
NVI Grade: 0=No iris neovascularization; 1=Fine surface neovascularization of the pupillary zone of the iris involving less than two quadrants; 2=Surface neovascularization of the pupillary zone of the iris involving more than two quadrants; 3=In addition to neovascularization of the pupillary zone, neovascularization of the ciliary zone of the iris and/or ectropion uveae involving one to three quadrants; 4=In addition to neovascularization of the pupillary zone, neovascularization of the ciliary zone of the iris and/or ectropion uveae involving more than three quadrants. The change in NVI grades categorized to "Improved" means improvement by at least one grade from baseline.
| Participants | Aflibercept 2 mg Intravitreal (IVT) Injection Group |
|---|---|
| Percentage of Participants Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Week 1 | 13 |
Collected over 30 days from administration in each patients. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept 2 mg Intravitreal (IVT) Injection Group | 0/16 (0%) | 1/16 (6.3%) | 6/16 (37.5%) |
| Event | Aflibercept 2 mg Intravitreal (IVT) Injection Group |
|---|---|
| PneumoniaInfections and infestations | 1/16 |
| Event | Aflibercept 2 mg Intravitreal (IVT) Injection Group |
|---|---|
| Eye painEye disorders | 4/16 |
| Corneal erosionEye disorders | 1/16 |
| Eye pruritusEye disorders | 1/16 |
| NasopharyngitisInfections and infestations | 1/16 |
| PneumoniaInfections and infestations | 1/16 |
| HeadacheNervous system disorders | 1/16 |
| Age, Continuous(Years) | Aflibercept 2 mg Intravitreal (IVT) Injection Group |
|---|---|
| Mean | 65.6 ± 12.9 |
| Sex: Female, Male(Participants) | Aflibercept 2 mg Intravitreal (IVT) Injection Group |
|---|---|
| Female | 4 |
| Male | 12 |
| Ethnicity (NIH/OMB)(Participants) | Aflibercept 2 mg Intravitreal (IVT) Injection Group |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 16 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Aflibercept 2 mg Intravitreal (IVT) Injection Group |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 16 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2018 to primary completion in Feb 2019, 4 months.
Results were first posted in Feb 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept